Literature DB >> 7828272

Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

L Milas1, N R Hunter, B Kurdoglu, K A Mason, R E Meyn, L C Stephens, L J Peters.   

Abstract

The kinetics of taxol-induced mitotic arrest and apoptosis in murine mammary carcinoma MCA-4 and ovarian carcinoma OCA-I tumors were determined to establish a possible causative relationship between mitotic arrest and apoptosis and to see whether these cellular effects of taxol would correlate with the extent of its antitumor efficacy. Mice bearing 8-mm tumors in a hind leg were given taxol i.v. at a dose of 10-80 mg/kg. Both tumors responded to taxol by significant growth delay or transient regression; in general, the response was greater as the dose of taxol was increased. For kinetics studies the mice were treated with 60 mg/kg taxol given once when tumors were 8 mm in size or twice, with the second dose being given 3 days after the first. At various times ranging from 1 to 96 h after treatment with taxol, tumors were histologically analyzed to quantify mitotic and apoptotic activity. After a single dose of taxol, mitotic arrest was visible at 1 h, and the mitotic index increased with time to reach peak values of 36% in MCA-4 tumors and 22% in OCA-I tumors at 9 h. The index then declined to a baseline of 1%-3% at 3 days for MCA-4 tumors and 1 day for OCA-I tumors. Apoptosis followed mitotic arrest, beginning at the time of peak mitotic arrest, increasing to the highest level of about 20% at 18-24 h after treatment and gradually declining to the normal level of 3%-6% after 3-4 days. Nuclear material progressively condensed in mitotically arrested cells, culminating in the frank appearance of multiple apoptotic bodies. The change in cell morphology plus the dynamics of apoptosis development imply that a large percentage of tumor cells arrested in mitosis by taxol die by apoptosis. Kinetic analysis undertaken after the second dose of taxol showed a considerably lower percentage of cells arrested in mitosis as compared with that seen after a single dose, and the induction of apoptosis by the second dose was minimal. However, the antitumor efficacy of the second dose of taxol was similar to or better than that of the first dose, implying that in addition to mitotic arrest and apoptosis, there exist other mechanisms by which taxol exerts its antitumor action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828272     DOI: 10.1007/BF00689448

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes.

Authors:  L Milas; N Hunter; K Mason; H R Withers
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

2.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation.

Authors:  A H Wyllie
Journal:  Nature       Date:  1980-04-10       Impact factor: 49.962

3.  Induction of apoptosis in murine tumors by cyclophosphamide.

Authors:  R E Meyn; L C Stephens; N R Hunter; L Milas
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Development of apoptosis in irradiated murine tumors as a function of time and dose.

Authors:  L C Stephens; N R Hunter; K K Ang; L Milas; R E Meyn
Journal:  Radiat Res       Date:  1993-07       Impact factor: 2.841

5.  Taxol sensitizes human astrocytoma cells to radiation.

Authors:  R B Tishler; C R Geard; E J Hall; P B Schiff
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 6.  Taxol: a review of its preclinical in vivo antitumor activity.

Authors:  W C Rose
Journal:  Anticancer Drugs       Date:  1992-08       Impact factor: 2.248

7.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

Review 8.  Induction of apoptosis--new targets for cancer chemotherapy.

Authors:  C Dive; C A Evans; A D Whetton
Journal:  Semin Cancer Biol       Date:  1992-12       Impact factor: 15.707

9.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies.

Authors:  R E Meyn; L C Stephens; K K Ang; N R Hunter; W A Brock; L Milas; L J Peters
Journal:  Int J Radiat Biol       Date:  1993-11       Impact factor: 2.694

View more
  39 in total

Review 1.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Authors:  Jie Wang; Ze Lu; Yue Gao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Nanomedicine (Lond)       Date:  2011-11       Impact factor: 5.307

2.  Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam Intensity Modulated Radiation Therapy in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation.

Authors:  Alice Y Ho; Ase Ballangrud; Guang Li; Gaorav P Gupta; Beryl McCormick; Richard Gewanter; Daphna Gelblum; Melissa Zinovoy; Boris Mueller; Borys Mychalczak; Pinaki Dutta; Karen Borofsky; Preeti Parhar; Marsha Reyngold; Lior Z Braunstein; Mohit Chawla; Kate Krause; Natasha Freeman; Chun Ting Siu; Zachary Cost; Brittany B Arnold; Zhigang Zhang; Simon N Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

Review 3.  Mitosis is not a key target of microtubule agents in patient tumors.

Authors:  Edina Komlodi-Pasztor; Dan Sackett; Julia Wilkerson; Tito Fojo
Journal:  Nat Rev Clin Oncol       Date:  2011-02-01       Impact factor: 66.675

4.  In Vitro Investigations on the Toxicity and Cell Death Induced by Tamoxifen on Two Non-Breast Cancer Cell Types.

Authors:  S. K. Majumdar; J. A. Valdellon; K. A. Brown
Journal:  J Biomed Biotechnol       Date:  2001

5.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Authors:  Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  Acute transient encephalopathy after weekly paclitaxel infusion.

Authors:  Sadık Muallaoğlu; Murat Koçer; Nilüfer Güler
Journal:  Med Oncol       Date:  2011-05-27       Impact factor: 3.064

7.  Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.

Authors:  N J Millenbaugh; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

Review 8.  Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

9.  Paclitaxel-induced apoptosis in human ovarian cancer cell line COC1.

Authors:  S Wang; Y Lu; D Ma
Journal:  J Tongji Med Univ       Date:  1999

Review 10.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.